Induction therapy after cardiac transplantation: A comparison of anti-thymocyte globulin and daclizumab in the prevention of acute rejection

Journal of Heart and Lung Transplantation

Volumn 24, Issue 3, 2005, Pages 296-302

  Carlsen, Jørn ^a   Johansen, Martin ^a   Boesgaard, Søren ^a   Andersen, Claus B ^a   Arendrup, Henrik ^a   Aldershvilet, Jan ^a   Mortensen, Svend Aage ^a  

^a Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTRIAXONE; COTRIMOXAZOLE; CYCLOSPORIN; DACLIZUMAB; GANCICLOVIR; IMTIX SANSTAT; ROCEPHALINE; SULFAMETHIZOLE; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; BACTERIAL INFECTION; CARDIAC GRAFT REJECTION; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEART MUSCLE BIOPSY; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; INFECTION RISK; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MALE; PERIOPERATIVE PERIOD; PNEUMOCYSTOSIS; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; SEPTICEMIA; SOLID TUMOR;

EID: 14644389386     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2003.12.014     Document Type: Article

References (20)

1. Lavee J., Bar-Zohar D., Har-Zahav Y., et al. Immunosuppression induction with rabbit antithymocyte globulin in heart transplantation patients 6-year experience at the Sheba Medical Center. Transplant Proc. 32:2000;737
2. Norman D.J. Antilymphocyte antibodies in the treatment of allograft rejection targets, mechanisms of action, monitoring, and efficacy. Semin Nephrol. 12:1992;315
3. Berglin E., Berggren H., Nilsson F., Svensson S. Immunosuppression with or without ATG in heart transplantation. Transplant Proc. 26:1994;1811
4. Carrier M., White M., Perrault L.P., et al. A 10-year experience with intravenous thymoglobuline in induction of immunosuppression following heart transplantation. J Heart Lung Transplant. 18:1999;1218
5. Wollenek G., Laufer G., Laczkovics A., Buxbaum P., Kober I. Comparison of a monoclonal anti-T cell antibody vs. ATG as prophylaxis after heart transplantation. Transplant Proc. 21:1989;2499
6. Przepiorka D., Kernan N.A., Ippoliti C., et al. Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease. Blood. 95:2000;83
7. Goebel J., Stevens E., Forrest K., Roszman T.L. Daclizumab (Zenapax) inhibits early interleukin-2 receptor signal transduction events. Transplant Immunol. 8:2000;153
8. van Gelder T., Baan C.C., Balk A.H., et al. Blockade of the interleukin (IL)-2/IL-2 receptor pathway with a monoclonal anti-IL-2 receptor antibody (BT563) does not prevent the development of acute heart allograft rejection in humans. Transplantation. 65:1998;405
9. Merion R.M. Current use of polyclonal antilymphocyte antibody preparations. Transplant Proc. 31:1999;2208
10. Beniaminovitz A., Itescu S., Lietz K., et al. Prevention of rejection in cardiac transplantation by blockade of the interleukin-2 receptor with a monoclonal antibody. N Engl J Med. 342:2000;613
11. Billingham M.E., Cary N.R.B., Hammond E.H., et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection heart rejection study group. J Heart Transplant. 9:1990;587-593
12. Krogsgaard K., Boesgaard S., Aldershvile J., Arendrup H., Mortensen S.A., Petterson G. Cytomegalovirus infection rate among heart transplant patients in relation to anti-thymocyte immunoglobulin induction therapy. Copenhagen Heart Transplant Group. Scand J Infect Dis. 26:1994;239
13. Brock M.V., Borja M.C., Ferber L., et al. Induction therapy in lung transplantation a prospective, controlled clinical trial comparing OKT3, anti-thymocyte globulin, and daclizumab. J Heart Lung Transplant. 20:2001;1282
14. Carswell C.I., Plosker G.L., Wagstaff A.J. Daclizumab a review of its use in the management of organ transplantation. BioDrugs. 15:2001;745
15. Beaufigeau M., Dumesnil D., Carrier M., White M., Pelletier G.B. Seven-year experience with rabbit antithymocyte globulin after cardiac transplantation at the Montreal Heart Institute. Transplant Proc. 29:(suppl):1997;10S
16. Cotts W.G., Johnson M.R. The challenge of rejection and cardiac allograft vasculopathy. Heart Fail Rev. 6:2001;227
17. Jimenez J., Kapadia S.R., Yamani M.H., et al. Cellular rejection and rate of progression of transplant vasculopathy a 3-year serial intravascular ultrasound study. J Heart Lung Transplant. 20:2001;393
18. Mehra M.R., Ventura H.O., Chambers R.B., Ramireddy K., Smart F.W., Stapleton D.D. The prognostic impact of immunosuppression and cellular rejection on cardiac allograft vasculopathy time for a reappraisal. J Heart Lung Transplant. 16:1997;743
19. Anguita M., Lopez-Rubio F., Arizon J.M., et al. Repetitive nontreated episodes of grade 1B or 2 acute rejection impair long-term cardiac graft function. J Heart Lung Transplant. 14:1995;452
20. Labarrere C.A., Nelson D.R., Park J.W. Pathologic markers of allograft arteriopathy insight into the pathophysiology of cardiac allograft chronic rejection. Curr Opin Cardiol. 16:2001;110